학술논문
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Document Type
Article
Author
Konstantinopoulos, Panagiotis A; Barry, William T; Birrer, Michael; Westin, Shannon N; Cadoo, Karen A; Shapiro, Geoffrey I; Mayer, Erica L; O'Cearbhaill, Roisin E; Coleman, Robert L; Kochupurakkal, Bose; Whalen, Christin; Curtis, Jennifer; Farooq, Sarah; Luo, Weixiu; Eismann, Julia; Buss, Mary K; Aghajanian, Carol; Mills, Gordon B; Palakurthi, Sangeetha; Kirschmeier, Paul; Liu, Joyce; Cantley, Lewis C; Kaufmann, Scott H; Swisher, Elizabeth M; D'Andrea, Alan D; Winer, Eric; Wulf, Gerburg M; Matulonis, Ursula A
Source
In The Lancet Oncology April 2019 20(4):570-580
Subject
Language
ISSN
1470-2045